Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Age-adjusted high-dose chemotherapy vs R-MP in elderly primary CNS lymphoma
DRKS00024085Phase 3Recruiting
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of rituximab, methotrexate, cytarabine and procarbazine in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Universitätsklinikum Freiburg. Started Mar 2023; status: recruiting.
02
Drugs
rituximabmethotrexatecytarabineprocarbazine
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on DRKS00024085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00024085.